Recent News

Posted by Burton on February 16th, 2015 in Headlines Corporate Announcements  ⟩  0 comments

Lee Biosolutions, Inc, a manufacturer and global provider of highly purified enzymes and related proteins for the life science, clinical diagnostic and the biotech healthcare industry, is proud to announce the addition of 3 new members to the Board of Directors reflecting its continued growth and expansion of the business.

President and CEO , J. Burton Lee says, “As a leader in the industry, we have a responsibility to maintain a strong articulated business strategy that will allow us to grow as our client base and product line continues to expand. I chose our members for their expertise, passion and commitment to make us a world class institution that will create a momentum in the market place that will be exciting for everyone doing business with us”

New Board Members

Matthew P. Lee is currently Vice-President with responsibilities that includes day to day operations of the business ensuring our company exceeds our customer expectations. Matthew holds a BS in Marketing Management from Missouri State University and joined Lee Biosolutions in 2012 as Logistics Manager. He was promoted to Vice-President in 2014 for his leadership and commitment to the business that has contributed to our highest growth in history of the company.

Daniel T. Fagan, PhD joined Lee Biosolutions in 2014 and brings a wealth of knowledge to the Board with his career spanning more than 37 years in both the Fine Chemical and Pharmaceutical Industries. His previous industrial experience includes the following: President of Sigma Chemical, General Manager of Mallinckrodt Peptides, President of PepTx, President, CEO and Chairman of the Board of Synthetech, Inc., Managing Director Brocair Partners as well as consulting over the last 15 years for various fine chemical, biotechnology and pharmaceutical companies.

Douglas D. Held, PhD joined Lee Biosolutions in 2010 and has focused on building the company’s core technical and scientific expertise and translating that expertise into new business opportunities. Doug has substantial experience in development and commercialization of processes for production and testing of biological molecules. Doug previous experiences includes a leadership positions at Singulex, Inc. and Sigma Aldrich, Inc. Doug has been issued four patents for biochemical methods for detection of human disease. Doug received a B.S in Chemistry and Biology from Iowa State University and a Ph.D. in Biochemistry from the University of Wisconsin, Madison, followed by post graduate training in Chemistry at the University of Iowa.

About Lee Bio

Lee Biosolutions is a producer of high purity finished enzymes and related proteins used by research institutions, IVD manufacturers and the biotech healthcare industries worldwide. LeeBio isknown for its expertise, leadership and support by clients because of its ability to closely partner with them in the development, purification, scale up and commercialization of innovative products.

Posted by Burton on January 19th, 2015 in Headlines Corporate Announcements  ⟩  0 comments

Lee Biosolutions is scheduled to expand into its new 41,000 sq. ft facility at 10850 Metro Ct, Maryland Heights MO in August after adding over $1 million dollars of improvements to the  of the of a state-of-the-art manufacturing facility. CEO & President, Burton Lee states, “ We are excited about our seamless transition to a larger facility which is designed for maximum flexibility for complex manufacturing processes. This expansion will enable LB to meet our ever growing product line as well as ensure improved on time delivery to our customers."  

Lee Biosolutions success has been the ability to develop some of the most successful products in the industry and the ability to provide expertise in purification, development and process chromatography to our clients.

Lee Biosolutions is a privately held corporation headquartered in St. Louis, MO manufacturing high purity finished enzymes and proteins for the diagnostic, academic and scientific industry worldwide. Our innovative preparative and analytical techniques allows us to meet both research and bulk cGMP manufacturing requirements.

Burton Lee

President and CEO

Posted by Burton on July 1st, 2014 in Headlines Corporate Announcements  ⟩  0 comments

ST LOUIS, July 2, 2014 -- Lee Biosolutions Inc, a leading biotech company in the healthcare field serving the Global diagnostic industry is proud to announce that it will expand into a new 40,786 Sq.ft facility in the City of Maryland Heights end of 4th quarter 2014 . The need for a new space is in response to the companies rising growth into new markets and increased demand for its products.

The building was previously home to one of the KV Pharmaceuticals cutting edge facilities that dotted the surrounding business landscape in St. Louis County. The Increased analytical lab space is needed for Lee Bio's increased growth for bioanalytical research and development projects and its ever expanding bulk manufacturing requirements. The added capacity and resources will help the company achieve its projected growth through 2017.

Burton Lee, President and CEO says ,"With the rapid growth we have seen over the last few years, our current facility was not able to keep up with demand. The new building supports our strategic objective to further expand our product lines, increase our capacity on key contract manufacturing products requiring larger cGMP processing clean rooms and to create operational efficiencies to meet our clients requirements."

The company plans on doubling its payroll by 2016 and is currently seeking qualified candidates to fill several positions by first quarter next year. The company has set up a career page to easily fill out and send in your resume.

Lee Biosolutions success in the aquisition of this outstanding new facility was achieved by having a great team which included Dan Dokovic from Intelica CRE, Kelly Shamel from Greensfelder Hemker & Gale, P.C, Jack Mannebach and Stephen Kuhn of Heartland Bank, Steve Grelle from the St. Louis Economic Development Partnership and The City Of Maryland Heights.

Lee Biosolutions is a key manufacturer of high purity enzymes and related proteins that include tumor markers, cardiac markerS, specialty diagnostic proteins for immunological diseases and biomarkers. The company is known internationally for developing some of the most successful formulations for research, diagnostic and therapeutic markets.

You can learn more about the company, its products, services and career opportunities by visiting its website at

Posted by Burton on May 5th, 2014 in Featured Community Partner Profiles  ⟩  0 comments


Lee Biosolutions has expanded our community outreach program to include a wonderful organization called Great Circle. Lee Biosolutions contributed $10,000 in 2013 and volunteered for Great Circle this holiday season that helped the Edgewood Children's Home and Hitchcock School programs. These caring individuals specialize in helping children that are abused , are in foster care and  have varying degrees of Autism and  Asperger's Syndrome.  Washington University works closely them developing innovative learning methods .   You can find dedicated counselors and therapists  going to a  child's home or in the worst case scenarios the child is brought to Edgewood where they can stay for months for special treatment.  This year we sponsored Career Day for the Science Class and had them visit our facility. We are also currently developing an internship program for these students.   

Posted by Burton on August 7th, 2013 in Headlines  ⟩  0 comments
Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.

According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II levels and possibly endoscopic examination.  ," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies  has been producing  tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."

Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. Lee currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit .